Abstract:<p class="a-plus-plus">Understanding the persistence of antibody in convalescent COVID-19 patients may help to answer the current major concerns such as the risk of reinfection, the protection period of vaccination and the possibility of building an active herd immunity. This retrospective cohort study included 172 COVID-19 patients who were hospitalized in Wuhan. A total of 404 serum samples were obtained over six months from hospitalization to convalescence. Antibodies in the specimens were quantitatively analyzed by the capture chemiluminescence immunoassays (CLIA). All patients were positive for the anti-SARS-CoV-2 IgM/IgG at the onset of COVID-19 symptoms, and the IgG antibody persisted in all the patients during the convalescence. However, only approximately 25% of patients can detect the IgM antibodies, IgM against N protein (N-IgM) and receptor binding domain of S protein (RBD-IgM) at the 27th week. The titers of IgM, N-IgM and RBD-IgM reduced to 16.7%, 17.6% and 15.2% of their peak values respectively. In contrast, the titers of IgG, N-IgG and RBD-IgG peaked at 4–5th week and reduced to 85.9%, 62.6% and 87.2% of their peak values respectively at the end of observation. Dynamic behavior of antibodies and their correlation in age, gender and severity groups were investigated. In general, the COVID-19 antibody was sustained at high levels for over six months in most of the convalescent patients. Only a few patients with antibody reducing to an undetectable level which needs further attention. The humoral immune response against SARS-CoV-2 infection in COVID-19 patients exhibits a typical dynamic of acquired immunity.</p>

What problem does this paper attempt to address?

This paper aims to explore the antibody persistence issue of COVID - 19 patients for up to six months from hospitalization to recovery. Specifically, the study focuses on the duration of the humoral immune response induced by SARS - CoV - 2 in COVID - 19 patients, which helps to address the current major concerns regarding the risk of reinfection, the protection period of vaccines, and the possibility of establishing active herd immunity. ### Research Background Coronavirus disease 2019 (COVID - 19), caused by severe acute respiratory syndrome coronavirus 2 (SARS - CoV - 2), has become a global health threat and has seriously affected socio - economic life. Since there are currently no specific anti - SARS - CoV - 2 virus treatment methods, adaptive immunity and supportive therapies are considered the main treatment sources. Almost all patients will produce antibodies after exposure to SARS - CoV - 2 infection. However, according to short - term analysis, specific antibodies against SARS - CoV - 2 can last for a few weeks or a little longer. These early records raise an important question: How long can the antibodies produced by COVID - 19 patients through acquired immunity last? This question is directly related to several major concerns: the risk of reinfection with the same serotype of SARS - CoV - 2, the validity period of vaccines, and the practical feasibility of herd immunity. ### Research Objectives To answer the above questions and address these concerns, researchers conducted a retrospective cohort study. By observing a group of COVID - 19 patients in Wuhan for up to six months, they accurately measured the persistence and intensity of the specific humoral immune response after SARS - CoV - 2 infection. The study used commercial chemiluminescence immunoassay kits and detectors (CLIA) to depict the kinetic pattern of the anti - SARS - CoV - 2 antibody response and revealed that the antibody levels of most patients can maintain a high level for at least six months during the recovery period. ### Main Findings - **Antibody Positivity Rate**: Within the first six weeks after the onset of symptoms, the peak positivity rates of IgM, N - IgM, and RBD - IgM were 96.6%, 90%, and 100% respectively. During the recovery period, the positivity rate of total antibodies did not decrease significantly, while the positivity rates of IgG, N - IgG, and RBD - IgG remained at a high level. The positivity rates of IgM, N - IgM, and RBD - IgM continued to decline, dropping to about 25% in the 27th week. - **Antibody Titer**: The titers of IgG, N - IgG, and RBD - IgG reached their peaks in the 4th to 5th weeks and hardly decreased throughout the observation period. In contrast, the titers of IgM, N - IgM, and RBD - IgM decreased rapidly, dropping to 16.7%, 17.6%, and 15.2% of their peaks respectively. The total antibody level remained high for more than six months, with an average value of 1961 AU/mL. - **Special Cases**: Some special cases were found in the study. These patients had abnormal immune responses, such as a sharp decline in antibody levels during the recovery period or failure to produce antibodies. ### Conclusions The research results show that S1 - total antibodies and RBD - IgG can be stably maintained for at least six months in COVID - 19 patients, which provides a reference for evaluating the long - term effectiveness of vaccines. In addition, most SARS - CoV - 2 - infected people (more than 98% in this study) can maintain high levels of S1 - total antibodies and RBD antibodies within six months, which is of great significance for establishing active herd immunity. However, the existence of some special cases suggests that further research on the immune mechanisms of these patients is needed to better understand the risk of reinfection.

Sustainability of SARS-CoV-2 Induced Humoral Immune Responses in COVID-19 Patients from Hospitalization to Convalescence Over Six Months